



Clinical Practice Guidelines

for the Management of **Melanoma** in Australia and New Zealand

Evidence-based
Best Practice
Guidelines

Approved by





Approved by the National Health and Medical Research Council
on 31 October 2008

© Cancer Council Australia/Australian Cancer Network/Ministry of Health, New Zealand (2008)

Australia: ISBN 978-0-9775060-7-1

New Zealand: ISBN (Print) 978-1-877509-04-9; ISBN (Electronic) 978-1-877509-05-6

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from The Cancer Council Australia/Australian Cancer Network. Requests and enquiries concerning reproduction and rights should be addressed to the Copyright Officer, Cancer Council Australia, GPO Box 4708, Sydney NSW 2001, Australia. Website: www.cancer.org.au Email: info@cancer.org.au

Approvals

Approval of the guidelines by the National Health and Medical Research Council (NHMRC) and New Zealand Guidelines Group (NZGG) is granted for a period not exceeding five years, at which date the approval expires. The NHMRC and NZGG expect that all guidelines will be reviewed no less than once every five years. Readers should check with the Australian Cancer Network or NZGG for any reviews or updates of these guidelines.

Disclaimer

This document is a general guide to appropriate practice, to be followed subject to the clinician's judgment and the patient's preference in each individual case.

The guidelines are designed to provide information to assist in decision-making. They are based on the best evidence available at time of compilation. The guidelines are not meant to be prescriptive.

Conflict of interest

The development of these clinical practice guidelines has been undertaken by a non-remunerated working party of the Australian Cancer Network and NZGG, with further support from the Cancer Institute NSW, the Cancer Council Australia and the Clinical Oncological Society of Australia.

Some members have received sponsorship to attend scientific meetings, been supported in the conducting of clinical trials, or have been involved in an advisory capacity by pharmaceutical and biochemical companies. Others have special interests indicated in specific chapters.

Periodic updates

New information arising in areas considered to be of importance will be posted periodically on the ACN (www.cancer.org.au/clinical_guidelines) and NZGG (www.nzgg.org.nz) websites. This information will not yet have been approved by the NHMRC but will be included as appropriate in future editions of the document.

These guidelines can be downloaded from the Australian Cancer Network website at www.cancer.org.au/skincancerguides or from the National Health and Medical Research Council website: www.nhmrc.gov.au, or (in New Zealand) from the NZGG website at www.nzgg.org.nz

Copies of this Guideline document can be ordered through the Australian Cancer Network on (02) 8063 4141 or email: acn@cancer.org.au, or (in New Zealand) through Wickliffe on (04) 496 2277. Order Nos. HP:4701 (guideline); HP: 4700 (practitioner summary); HP: 4699 (public).

Suggested citation

Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008).